Outlook Therapeutics won FDA approval for LYTENAVA for wet age-related macular degeneration, the first and only approved ophthalmic bevacizumab in retina care.

Outlook Therapeutics won FDA approval for LYTENAVA for wet age-related macular degeneration, the first and only approved ophthalmic bevacizumab in retina care. The decision gives physicians a new anti-VEGF option and sharpens Outlook’s position in a crowded market.